Volume 16, Number 2—February 2010
Cost-effectiveness of Pharmaceutical-based Pandemic Influenza Mitigation Strategies1
|Strategy no.||Net cost||Incremental cost||LYS||Incremental LYS||Incremental cost per LYS†|
*LYS, life-year saved. Costs and life-years discounted at 5% annually; all costs calculated in 2005 Australian dollars.
†Rounded to the nearest whole dollar.
- Page created: December 10, 2010
- Page last updated: December 10, 2010
- Page last reviewed: December 10, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)